神经炎症生物标记在non-fluent / agrammatic变体原发性进行性失语和/或言语失用症(p12 - 3.002)

摘要目的:确定转运蛋白的解剖特异性蛋白质18 kDa (TSPO)成像在non-fluent / agrammatic变体原发性进行性失语(nfvPPA)和/或言语失用症(代谢)。

背景:额颞叶痴呆的神经炎症,标志和一个潜在的治疗目标,研究稀疏在活的有机体内。我们使用¹¹C-PBR28宠物来衡量TSPO水平nfvPPA)患者和/或代谢。

设计/方法:16例(9/16的女性,年龄65±5.9年)nfvPPP /市场接受的宠物使用¹¹C-PBR28和¹⁸F-flortaucipir。患者宠物amyloid-negative除了两个,non-AD flortaucipir宠物。三十健康对照组(17/30的女性,年龄66±9.3年)接受了PET成像使用¹¹控制C-PBR28(13)或¹⁸F-flortaucipir控制(17)。V_T值¹¹C-PBR28计算Logan情节和metabolite-corrected动脉输入函数。为¹⁸F-flortaucipir,小脑灰质的SUV比率计算t = 80 - 100分钟。一个完整的进行因子分析V_T和SUVR值。

结果:控制相比,患者增加V_T和SUVR值(p < 0.001未修正的)左低,中间和卓越的额叶脑回,左壳核和苍白球。然而,吸收峰值¹⁸F-flortaucipir在布洛卡区局部,震中病理学,而分布¹¹C-PBR28V_T在额叶更广泛,包括中央前回、额叶以外的其他地区,随着supramarginal回和颞上沟,以及小面积后的右额下回。

结论:¹¹C-PBR28和¹⁸F-flortaucipir吸收模式对应于解剖区域已知参与nfvPPA和失用症的演讲。因此,¹¹C-PBR28似乎nfvPPA适合检测存在的放射性配体。此外,更广泛的解剖异常的分布¹¹C-PBR28吸收,相比¹⁸F-flortaucipir吸收,表明炎症是关键在nfvPPA病理过程的发展。

披露:Belen帕斯卡的机构收到NIH的研究支持。Belen帕斯卡的机构收到NIH的研究支持。昆汀恐慌没有披露。布拉德伯里女士没有披露。阿普尔顿女士没有披露。保罗到Fregonara没有披露。Nakawah博士没有披露。Faridar博士没有披露。Masdeu博士已经收到个人薪酬在500 - 4999美元的范围为在科学咨询服务或数据安全监测委员会生原体。Masdeu博士已经收到个人薪酬在500 - 4999美元的范围在生原体的演讲人。 Dr. Masdeu has received personal compensation in the range of $50,000-$99,999 for serving as an Expert Witness for NCAA. Dr. Masdeu has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Blank and Rome. The institution of Dr. Masdeu has received research support from NIH. The institution of Dr. Masdeu has received research support from Moody Foundation. The institution of Dr. Masdeu has received research support from Abbvie. The institution of Dr. Masdeu has received research support from Biogen. The institution of Dr. Masdeu has received research support from Eli Lilly. The institution of Dr. Masdeu has received research support from Eisai. The institution of Dr. Masdeu has received research support from Novartis. Dr. Masdeu has received publishing royalties from a publication relating to health care. Dr. Masdeu has received personal compensation in the range of $100,000-$499,999 for serving as a Director, Nantz Nal Alzheimer Center with HOUSTON METHODIST NEUROLOGICAL INSTITUTE.